STAT6 correlates with response to immune checkpoint blockade therapy and predicts worse survival in thyroid cancer

Biomark Med. 2020 Jul;14(11):955-967. doi: 10.2217/bmm-2020-0125.

Abstract

Aim: The signal transducer and activator of transcription (STAT) family has been documented. However, the role of STATs in thyroid cancer was not fully studied. Materials & methods: A survival analysis of STATs was performed. The function modulated by STAT6 was examined. The role of STAT6 in cancer immune infiltrates and immune checkpoint blockade molecules was investigated. Results: Only low STAT6 expression correlated with worse survival. STAT6 is involved in cell cycle, cell adhesion, apoptosis and notch signaling pathways. STAT6 was significantly positively associated with immune infiltration of B cells, CD4+ T cells, neutrophils, macrophages, dendritic cells and the immune checkpoint blockade molecules programmed cell death-ligand 1, programmed cell death-ligand 2 and cytotoxic T-lymphocyte-associated protein 4. Conclusion: STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma.

Keywords: STAT6; checkpoint blockade; immune; marker; prognosis; thyroid carcinoma.

MeSH terms

  • Apoptosis / drug effects
  • Biomarkers, Tumor / metabolism
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Immune Checkpoint Inhibitors / therapeutic use
  • STAT6 Transcription Factor / metabolism*
  • Signal Transduction / drug effects
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / immunology
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors
  • STAT6 Transcription Factor
  • STAT6 protein, human